Biodesix (BDSX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BDSX Stock Forecast

Biodesix stock forecast is as follows: an average price target of $3.00 (represents a 115.83% upside from BDSX’s last price of $1.39) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

BDSX Price Target

The average price target for Biodesix (BDSX) is $3.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 115.83% upside from BDSX's last price of $1.39.

BDSX Analyst Ratings

Buy

According to 3 Wall Street analysts, Biodesix's rating consensus is 'Buy'. The analyst rating breakdown for BDSX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Biodesix Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 16, 2024	Sung Ji Nam	Scotiabank	$3.00	$1.82	64.84%	115.83%
Jul 26, 2024	Bill Bonello	Craig-Hallum	$3.00	$1.68	78.57%	115.83%

The latest Biodesix stock forecast, released on Sep 16, 2024 by Sung Ji Nam from Scotiabank, set a price target of $3.00, which represents a 64.84% increase from the stock price at the time of the forecast ($1.82), and a 115.83% increase from BDSX last price ($1.39).

Biodesix Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$3.00
Last Closing Price	$1.39	$1.39	$1.39
Upside/Downside	-100.00%	-100.00%	115.83%

In the current month, the average price target of Biodesix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biodesix's last price of $1.39. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	New Rating	Rating Change
Sep 16, 2024	Scotiabank	Outperform	Initialise
Jul 26, 2024	Craig-Hallum	Buy	Initialise
May 13, 2024	Cowen & Co.	Buy	Initialise

Biodesix's last stock rating was published by Scotiabank on Sep 16, 2024. The company Initialise its BDSX rating from "null" to "Outperform".

Biodesix Financial Forecast

Biodesix Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	$13.49M	$11.87M	$9.06M	$9.61M	$11.11M	$10.95M	$6.55M	$7.22M	$6.53M	$11.88M	$28.87M	$27.03M	$9.19M
Avg Forecast	$25.27M	$23.18M	$22.29M	$20.22M	$19.81M	$18.57M	$16.13M	$14.18M	$15.62M	$14.12M	$11.67M	$8.71M	$10.77M	$10.15M	$8.83M	$6.47M	$7.29M	$6.15M	$20.58M	$26.23M	$15.47M	$8.66M
High Forecast	$25.75M	$23.62M	$22.71M	$20.61M	$20.19M	$18.62M	$16.13M	$14.18M	$15.77M	$14.24M	$11.90M	$8.88M	$10.98M	$10.15M	$8.83M	$6.47M	$7.29M	$6.15M	$20.58M	$26.23M	$15.47M	$8.66M
Low Forecast	$24.78M	$22.73M	$21.86M	$19.83M	$19.43M	$18.51M	$16.13M	$14.18M	$15.46M	$14.00M	$11.45M	$8.54M	$10.56M	$10.15M	$8.83M	$6.47M	$7.29M	$6.15M	$20.58M	$26.23M	$15.47M	$8.66M
# Analysts	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	0.96%	1.02%	1.04%	0.89%	1.09%	1.24%	1.01%	0.99%	1.06%	0.58%	1.10%	1.75%	1.06%

Biodesix's average Quarter revenue forecast for Dec 23 based on 2 analysts is $15.62M, with a low forecast of $15.46M, and a high forecast of $15.77M. BDSX's average Quarter revenue forecast represents a 15.75% increase compared to the company's last Quarter revenue of $13.49M (Sep 23).

Biodesix EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-7.17M	$-10.93M	$-16.35M	$-13.89M	$-8.94M	$-10.18M	$-13.18M	$-19.95M	$-9.17M	$-9.81M	$-5.56M	$-3.10M	$3.43M
Avg Forecast	$-19.53M	$-17.91M	$-17.22M	$-15.63M	$-15.31M	$-14.35M	$-12.47M	$-10.96M	$-12.07M	$-10.91M	$-9.02M	$-6.73M	$-8.32M	$-7.78M	$-6.76M	$-9.95M	$-5.58M	$-4.71M	$-15.76M	$-3.60M	$-11.84M	$-6.63M
High Forecast	$-19.15M	$-17.57M	$-16.89M	$-15.33M	$-15.02M	$-14.31M	$-12.47M	$-10.96M	$-11.95M	$-10.82M	$-8.85M	$-6.60M	$-8.16M	$-7.78M	$-6.76M	$-7.96M	$-5.58M	$-4.71M	$-15.76M	$-2.88M	$-11.84M	$-6.63M
Low Forecast	$-19.90M	$-18.26M	$-17.55M	$-15.93M	$-15.61M	$-14.39M	$-12.47M	$-10.96M	$-12.19M	$-11.00M	$-9.19M	$-6.86M	$-8.48M	$-7.78M	$-6.76M	$-11.93M	$-5.58M	$-4.71M	$-15.76M	$-4.32M	$-11.84M	$-6.63M
Surprise %	-	-	-	-	-	-	-	-	-	0.66%	1.21%	2.43%	1.67%	1.15%	1.51%	1.33%	3.57%	1.95%	0.62%	1.55%	0.26%	-0.52%

1 analysts predict BDSX's average Quarter EBITDA for Dec 20 to be $-11.84M, with a high of $-11.84M and a low of $-11.84M. This is -445.06% lower than Biodesix's previous annual EBITDA (Sep 20) of $3.43M.

Biodesix Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-10.95M	$-13.36M	$-17.12M	$-26.79M	$-16.79M	$-20.02M	$-16.79M	$-5.76M	$-11.51M	$-11.40M	$-6.96M	$-4.53M	$-8.85K
Avg Forecast	$-6.67M	$-7.53M	$-8.47M	$-10.11M	$-9.96M	$-10.70M	$-13.47M	$-20.79M	$-15.96M	$-21.46M	$-30.17M	$-34.62M	$-40.60M	$-41.67M	$-59.13M	$-11.69M	$-62.56M	$-60.72M	$-36.46M	$-4.50M	$-51.10M	$-36.46M
High Forecast	$-6.50M	$-7.34M	$-8.26M	$-9.86M	$-9.71M	$-10.43M	$-13.13M	$-20.27M	$-11.60M	$-20.92M	$-29.41M	$-33.75M	$-39.59M	$-41.67M	$-59.13M	$-9.35M	$-62.56M	$-60.72M	$-36.46M	$-3.60M	$-51.10M	$-36.46M
Low Forecast	$-6.83M	$-7.72M	$-8.68M	$-10.36M	$-10.21M	$-10.97M	$-13.80M	$-21.31M	$-18.86M	$-21.99M	$-30.92M	$-35.48M	$-41.62M	$-41.67M	$-59.13M	$-14.03M	$-62.56M	$-60.72M	$-36.46M	$-5.41M	$-51.10M	$-36.46M
Surprise %	-	-	-	-	-	-	-	-	-	0.51%	0.44%	0.49%	0.66%	0.40%	0.34%	1.44%	0.09%	0.19%	0.31%	1.55%	0.09%	0.00%

Biodesix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BDSX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Biodesix SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$15.50M	$16.65M	$18.99M	$16.63M	$15.11M	$15.23M	$14.49M	$13.56M	$13.61M	$11.43M	$11.93M	$39.04M	$7.88M
Avg Forecast	$29.93M	$27.45M	$26.39M	$23.95M	$23.46M	$21.99M	$19.11M	$16.79M	$18.49M	$16.72M	$13.82M	$10.32M	$12.76M	$11.91M	$10.35M	$7.58M	$8.55M	$7.22M	$24.13M	$7.72M	$18.13M	$10.15M
High Forecast	$30.50M	$27.98M	$26.90M	$24.41M	$23.91M	$22.05M	$19.11M	$16.79M	$18.68M	$16.86M	$14.09M	$10.51M	$13.00M	$11.91M	$10.35M	$7.58M	$8.55M	$7.22M	$24.13M	$9.26M	$18.13M	$10.15M
Low Forecast	$29.35M	$26.92M	$25.88M	$23.49M	$23.01M	$21.92M	$19.11M	$16.79M	$18.31M	$16.58M	$13.56M	$10.12M	$12.51M	$11.91M	$10.35M	$7.58M	$8.55M	$7.22M	$24.13M	$6.17M	$18.13M	$10.15M
Surprise %	-	-	-	-	-	-	-	-	-	0.93%	1.20%	1.84%	1.30%	1.27%	1.47%	1.91%	1.59%	1.89%	0.47%	1.55%	2.15%	0.78%

Biodesix's average Quarter SG&A projection for Dec 23 is $18.49M, based on 2 Wall Street analysts, with a range of $18.31M to $18.68M. The forecast indicates a 19.34% rise compared to BDSX last annual SG&A of $15.50M (Sep 23).

Biodesix EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-0.14	$-0.17	$-0.22	$-0.46	$-0.42	$-0.51	$-0.54	$-0.21	$-0.41	$-0.41	$-0.26	$-0.25	$-0.00
Avg Forecast	$-0.05	$-0.05	$-0.06	$-0.07	$-0.07	$-0.07	$-0.09	$-0.14	$-0.11	$-0.15	$-0.21	$-0.24	$-0.28	$-0.33	$-0.47	$-0.42	$-0.49	$-0.48	$-0.29	$-0.17	$-0.40	$-0.29
High Forecast	$-0.04	$-0.05	$-0.06	$-0.07	$-0.07	$-0.07	$-0.09	$-0.14	$-0.08	$-0.14	$-0.20	$-0.23	$-0.27	$-0.33	$-0.47	$-0.42	$-0.49	$-0.48	$-0.29	$-0.17	$-0.40	$-0.29
Low Forecast	$-0.05	$-0.05	$-0.06	$-0.07	$-0.07	$-0.07	$-0.09	$-0.15	$-0.13	$-0.15	$-0.21	$-0.24	$-0.28	$-0.33	$-0.47	$-0.42	$-0.49	$-0.48	$-0.29	$-0.17	$-0.40	$-0.29
Surprise %	-	-	-	-	-	-	-	-	-	0.95%	0.82%	0.93%	1.66%	1.28%	1.10%	1.27%	0.43%	0.86%	1.43%	1.49%	0.62%	0.00%

According to undefined Wall Street analysts, Biodesix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BDSX previous annual EPS of $NaN (undefined).

Biodesix Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRIO	DarioHealth	$0.71	$10.75	1414.08%	Buy
STIM	Neuronetics	$1.30	$8.00	515.38%	Buy
BDSX	Biodesix	$1.39	$3.00	115.83%	Buy
ACRS	Aclaris Therapeutics	$3.26	$6.00	84.05%	Buy
CSTL	Castle Biosciences	$28.14	$40.50	43.92%	Buy
XGN	Exagen	$5.80	$5.00	-13.79%	Buy

BDSX Forecast FAQ

Is Biodesix a good buy?

Yes, according to 3 Wall Street analysts, Biodesix (BDSX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BDSX's total ratings.

What is BDSX's price target?

Biodesix (BDSX) average price target is $3 with a range of $3 to $3, implying a 115.83% from its last price of $1.39. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Biodesix stock go up soon?

According to Wall Street analysts' prediction for BDSX stock, the company can go up by 115.83% (from the last price of $1.39 to the average price target of $3), up by 115.83% based on the highest stock price target, and up by 115.83% based on the lowest stock price target.

Can Biodesix stock reach $2?

BDSX's average twelve months analyst stock price target of $3 supports the claim that Biodesix can reach $2 in the near future.

What are Biodesix's analysts' financial forecasts?

Biodesix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $68.7M (high $69.13M, low $68.26M), average EBITDA is $-53.09M (high $-52.751M, low $-53.428M), average net income is $-54.92M (high $-53.545M, low $-56.288M), average SG&A $81.35M (high $81.87M, low $80.83M), and average EPS is $-0.375 (high $-0.366, low $-0.385). BDSX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $90.96M (high $92.7M, low $89.21M), average EBITDA is $-70.298M (high $-68.943M, low $-71.645M), average net income is $-32.776M (high $-31.955M, low $-33.592M), average SG&A $107.72M (high $109.78M, low $105.64M), and average EPS is $-0.224 (high $-0.218, low $-0.23).

Did the BDSX's actual financial results beat the analysts' financial forecasts?

Based on Biodesix's last annual report (Dec 2023), the company's revenue was $49.09M, which missed the average analysts forecast of $50.12M by -2.06%. Apple's EBITDA was $-41.342M, beating the average prediction of $-38.734M by 6.73%. The company's net income was $-52.146M, missing the average estimation of $-102M by -48.98%. Apple's SG&A was $67.39M, beating the average forecast of $59.35M by 13.54%. Lastly, the company's EPS was $-0.64, missing the average prediction of $-0.699 by -8.39%. In terms of the last quarterly report (Sep 2023), Biodesix's revenue was $13.49M, missing the average analysts' forecast of $14.12M by -4.45%. The company's EBITDA was $-7.172M, missing the average prediction of $-10.912M by -34.27%. Biodesix's net income was $-10.949M, missing the average estimation of $-21.457M by -48.97%. The company's SG&A was $15.5M, missing the average forecast of $16.72M by -7.32%. Lastly, the company's EPS was $-0.14, missing the average prediction of $-0.147 by -4.55%